Opinion|Videos|May 12, 2025
Applying Trial Data to Real-World Practice in ALK+ NSCLC
Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ non–small cell lung cancer (NSCLC).
Advertisement
Episodes in this series
Real-World Settings and Evolution of Frontline Therapy
Key Themes:
- Comparison of clinical trial outcomes to real-world patient experiences
- Impact of clinical data (ALINA, CROWN, eXalt3) on frontline therapy choices
- Evolving perspective on frontline therapies for ALK+ NSCLC
Notable Insights:
- Grizzard addressed how well outcomes from trials like CROWN and eXalt3 reflect real-world patient experiences
Dr Dietrich summarized how recent clinical data has changed the landscape of frontline therapies for ALK+ NSCLC
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
5